HealthTree Logo
search more_vert
person Sign In / Create Account
Evorpacept - A Next-Generation CD47 Inhibitor in Phase I Study for Patients With Relapsed-Refractory Lymphoma
Posted: May 06, 2024
Evorpacept - A Next-Generation CD47 Inhibitor in Phase I Study for Patients With Relapsed-Refractory Lymphoma image

Follicular lymphoma is one of the most common subtypes of non-Hodgkin lymphoma. These cancers affect the lymphatic system, a part of the body's immune system. Specifically, follicular lymphoma affects B-lymphocytes, a type of white blood cell. 

Follicular lymphoma cells express CD47 to avoid detection by healthy immune cells, which are in charge of eliminating cancer cells.

ALX Oncology is developing a next-generation checkpoint inhibitor called evoparcept. It is designed to bind and block CD47 and avoid the side effects seen with other CD47-blocking therapies. When it binds to CD47, evorparcept helps signal the immune response against lymphoma cells.

Evorparcept is being studied in combination with rituximab and lenalidomide in a phase 1/2 trial that is currently enrolling patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). 

Initial Results with Evorpacept in Follicular Lymphoma 

Initial Results with Evorpacept in Follicular Lymphoma They treated 20 patients with NHL, of which 15 were follicular lymphoma patients. Researchers reported that adding evorpacept to the standard treatment (rituximab and lenalidomide) improved the number of responses compared to what is expected when treating with rituximab and lenalidomide alone. 

After one year, 90% of patients treated with the triple combination are alive, and 70% are still in remission. Evoparcept has been considered to be well-tolerated, with the most common side effects being fatigue, low blood counts, and increased liver enzyme levels. 

This clinical trial is ongoing, but it helped identify the optimal dose to move forward into a larger phase 2 study. 

Expanding treatment options and enrolling in clinical trials for relapsed and refractory patients is crucial for finding a potential cure for all! 

With our clinical trial finder within HealthTree Cure Hub, you can find up-to-date clinical trials recruiting patients in your area! 



The author Jimena Vicencio

about the author
Jimena Vicencio

Jimena is an International Medical Graduate who is part of the HealthTree Patient Experience team. She loves learning new things led by her curiosity, playing with her pets, and exercising in her free time.